Drug intelligence / Profile preview

BT-101

Development stage: Phase 1
Lead developer: Bodihekang
Modality: Small Molecules
Administration: Oral

Overview

BT-101 is a preclinical-stage small molecule modulator of an undisclosed G-protein coupled receptor (GPRx), currently under development by Benethera. The program is primarily focused on treating Inflammatory Bowel Disease (IBD), but also shows potential for other inflammatory and autoimmune conditions, including asthma, multiple sclerosis, Celiac disease, and IgA nephropathy. By targeting a specific GPRx, BT-101 aims to modulate immune responses associated with these chronic diseases.

Targets

GPR174 (G protein-coupled receptor 174)

Beyond the preview

Go deeper on BT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT-101.

Explore the full profile